DVA.V - Delivra Corp.

TSXV - TSXV Delayed Price. Currency in CAD
0.325
+0.015 (+4.84%)
At close: 2:13PM EDT
Stock chart is not supported by your current browser
Previous Close0.310
Open0.315
Bid0.325 x 0
Ask0.330 x 0
Day's Range0.300 - 0.330
52 Week Range0.270 - 0.590
Volume49,902
Avg. Volume31,643
Market Cap15.424M
Beta-2.74
PE Ratio (TTM)N/A
EPS (TTM)-0.038
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Baystreetlast month

    Stocks in play: Delivra Corp.

    Reported its financial results for the three months ended March 31, 2018. Revenues came in at $995,938,000, ...

  • CNW Grouplast month

    Delivra Announces First Quarter Financial Results

    TORONTO, May 22, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") reported its financial results for the three months ended March 31, 2018. Delivra's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").

  • CNW Group2 months ago

    Delivra Exposes that the Cannabis Market Requires Further Standardization and Rigourous Testing

    TORONTO, May 3, 2018 /CNW/ - Delivra Corp. ("Delivra", or "the Company") today announced the publication of their analytical evaluation of a variety of third-party over-the-counter hemp consumer products for tetrahydrocannabinol ("THC") and cannabidiol ("CBD") content to further develop its internal expertise and evaluate the consumer landscape. The publication conducted out of Delivra's research lab in Charlottetown, PEI and partially funded by Skills-PEI and by the Atlantic Canada Opportunities Agency, concluded that most third-party consumer products met the federal guidelines on THC content. As a tool, the testing method is amenable to a variety of consumer products indicating its general applicability towards cannabis oils and more complex materials like creams and edibles.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Annidis, RNC Minerals, Delivra and The Hydropothecary

    NEW YORK, NY / ACCESSWIRE / April 26, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • CNW Group2 months ago

    Delivra's Successful Product Development Strategy Yields Product Line Expansions - Including Cannabis-Related Products

    TORONTO, April 26, 2018 /CNW/ - Delivra Corp. ("Delivra", or "the Company") today announced that its R&D, pre-clinical and clinical teams have successfully developed and tested line-extension products using its precision topical delivery system platform, DelivraTM. With the assistance and support of Emergence, Canada's virtual incubator that supports the growth of innovative bioscience and food sector ventures, Delivra has developed its strategy and executed on ready to use products for OTC line extensions that will compliment its already existing successful LivRelief products, and is ready for the upcoming legalization of cannabis with its vast array of cannabis-related products for third party distributors for different disease indications. This acceleration of LivRelief sales growth in the topical OTC category will involve additional unique SKUs at existing accounts and an enhancement of the distribution channels, which is now over 5,200 pharmacy/grocery and natural products stores.

  • Baystreet2 months ago

    Stocks in play: Delivra Corp.

    Announced the ability to treat pain directly with a topical version of Advil™ (ibuprofen). Testing for ...

  • CNW Group2 months ago

    Delivra successfully demonstrates targeted pain relief with topical ibuprofen

    TORONTO, April 24, 2018 /CNW/ - Delivra Corp. ("Delivra", or "the Company") today announced the ability to treat pain directly with a topical version of Advil™ (ibuprofen). In pre-clinical testing, undertaken by an independent third-party research organization, the Delivra-ibuprofen formulation provided sustained pain reduction. In the study, Delivra-ibuprofen was tested in an acute canine model of arthritis where the formulation performed equally or better for swelling and pain reduction compared its oral equivalent and test controls.

  • CNW Group2 months ago

    Delivra Publishes Pivotal Results on the Cholesterol & Lipid Lowering Agent Berberine

    TORONTO, April 18, 2018 /CNW/ - Delivra Corp. ("Delivra", or "the Company") today announced the publication of positive data from a pre-clinical study demonstrating the safety and greater bioavailability of transdermal berberine and dihydroberberine (DHB) for the prevention and treatment of cardiovascular disease related to high cholesterol and triglyceride levels. "This promising data supports Delivra's research and proprietary development of topical berberine and DHB's effectiveness to successfully reduce cholesterol and triglyceride levels. In certain cases, this treatment may provide a natural alternative to the use of statin drugs.

  • Baystreet2 months ago

    Stocks in play: Delivra Corp.

    Reported its financial results for the 12 months ended December 31, 2017. The company reported record ...

  • CNW Group2 months ago

    Delivra announces 20% sales growth for 2017

    TORONTO , April 10, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") reported its financial results for the three and twelve months ended December 31, 2017 . All ...

  • CNW Group3 months ago

    Delivra Corp. Completes $1,246,498.20 Non-Brokered Financing

    TORONTO, April 5, 2018 /CNW/ - Delivra Corp. (TSXV:DVA.V - News) (the "Company" or "Delivra") has completed a non-brokered private placement through the issuance of 3,561,423 units ("Units", as defined below) of the Company for gross proceeds of $1,246,498.20 (the "Offering"). Each Unit consists of one common share of the Company (a "Share") and one share purchase warrant (a "Warrant"). Each whole Warrant will entitle the holder to purchase one Share at a price of $0.50 per Share for 24 months from the date of closing, subject to the option of the Company, in the event that the closing price of Shares on the TSX Venture Exchange (the "TSXV") equals or exceeds $0.90 per Share for 10 consecutive days, to accelerate the expiry of the Warrants to 30 days after acceleration notice (the "Acceleration Option").

  • ACCESSWIRE3 months ago

    Today’s Research Reports on RNC Minerals, Delivra, The Hydropothecary and VentriPoint Diagnostics

    NEW YORK, NY / ACCESSWIRE / March 28, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ACCESSWIRE4 months ago

    Canadian Exchanges Stock Scanner Maple Leaf Green World GreenSpace Brands Naturally Splendid Enterprises and Delivra

    LONDON, UK / ACCESSWIRE / February 15, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Consumer-Packaged Goods industry: Maple Leaf Green ...

  • CNW Group5 months ago

    Delivra Signs Distribution Agreement With NKS Health for Ready to Market Compounded Finished Products to Medical Doctors

    TORONTO, Feb. 1, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") announced today that it has signed a non-exclusive distribution agreement with NKS Health Ltd. ("NKS"), granting NKS the right to compound, distribute, promote, market and sell new unique pharmaceutical compounded product formulas developed by Delivra. The goal of the agreement is to build a partnership to both grow awareness and increase volume of sales for the Company's pharmaceutical pipeline. NKS will promote Delivra's cream-base therapeutics to physicians, hospitals and clinics in Canada through its network.  Delivra has developed a suite of compounded products for pain, anxiety and diabetic foot ulcers.

  • Baystreet5 months ago

    Stocks in play: Delivra Corp

    Has signed a joint venture agreement using Delivra's revolutionary, proprietary topical therapeutic ...

  • CNW Group5 months ago

    Delivra develops a revolutionary topical cream utilizing cannabis and opioid molecules for safer delivery in patients with chronic pain and anxiety

    TORONTO, Jan. 16, 2018 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") announced today the Company has developed a revolutionary, proprietary topical cream base therapeutic, DelivraTMN, for molecules of Cannabis, Cannabis-like and opioids, for a safer, more targeted and consistent delivery to patients afflicted with chronic pain and anxiety. "Our goal is to develop innovative products using our proprietary topical delivery platform (DelivraTM) to meet significant unmet medical needs and improve quality of life. With our proven patent-pending technology and formulation expertise, we have created medical grade products that have shown significant efficacy and predictable outcomes to patients," said Dr. Joseph Gabriele, CEO of Delivra.

  • ACCESSWIRE5 months ago

    Canadian Exchanges Stock Scanner, Maple Leaf Green World, GreenSpace Brands, Naturally Splendid Enterprises, and Delivra

    LONDON, UK / ACCESSWIRE / January 12, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Consumer Packaged Goods industry: Maple Leaf Green World, ...

  • Marketwired7 months ago

    Delivra Announces Record Sales Growth for the Quarter

    Delivra Corp. reported its financial results for the three and nine months ended September 30, 2017. All figures are reported in CDN dollars , unless otherwise indicated. Delivra's financial...

  • Marketwired9 months ago

    Delivra Appoints Chief Marketing Officer

    Delivra Corp. , announced today the appointment of Howard Lichtman to the position of Chief Marketing Officer . "Howard is a highly-experienced, accomplished business leader with a proven track......